$ABT

Morrone Louis H. sold $643K of ABT

Morrone Louis H. (EXECUTIVE VICE PRESIDENT) sold 5,850 shares of ABBOTT LABORATORIES (ABT) at $109.83 ($0.64M total) on 2026-08-11.

Original reporting
SEC EDGAR · Morrone Louis H.
Published Aug 13, 2026, 9:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ABT
Neutral
medium confidence
Mentioned
$ABT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABTNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may briefly watch for sentiment effects from insider selling, but there is no accompanying fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs; the article provides no stated reason for the sale.

Relevance 5/10Novelty 3/10Timing: filed after-hours on 2026-08-13, covering a sale dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Abbott Laboratories (ABT).

Company-level read

Ticker impact

$ABTNeutralMedium confidence
Context

Abbott Laboratories Form 4 shows EVP Morrone Louis H. sold 5,850 shares at $109.83 on 2026-08-11 for about $642.5K.

Expected impact

Low likelihood of a sustained price move; any near-term impact would be sentiment-driven and typically fades.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no new company-specific operational, financial, or regulatory information.

Market effects

No clear sector read-through; insider sales are common and not a sector catalyst by themselves.

None indicated.

None indicated.

Counterpoint

Because the filing states no pre-arranged 10b5-1 plan, some traders may interpret the sale as higher near-term risk, even though insider sales are often non-informational.

Key entities

  • Abbott Laboratories

    Subject of the Form 4 insider transaction disclosure.

  • Morrone Louis H.

    Executive Vice President who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABTLow

Whistleblowers Help DOJ Achieve $385 Million Settlement with Abbott Laboratories for Contaminated Infant Formula Sold to Government Programs – RACmonitor

Abbott Laboratories agreed to a $385M settlement with the DOJ for alleged false claims related to contaminated infant formula sold to government programs. The settlement resolves claims that Abbott failed to meet manufacturing standards at its Michigan and Arizona facilities. The company did not admit liability. The settlement includes $348.7M to the federal government and $36.3M to state Medicaid programs. Three whistleblowers will receive $69M for their role in exposing the allegations.

$ABTLow

Abbott Laboratories Contamination Lawsuit Ends in $385 Million Settlement — But Nobody's Admitting Anything

Abbott Laboratories agreed to a $385M settlement to resolve a False Claims Act lawsuit over alleged contamination at its Sturgis, Michigan, and Casa Grande, Arizona, plants. The DOJ and state AGs filed the suit, citing poor conditions and alleged concealment of contamination tests. Abbott denied liability. The 2022 recall caused widespread formula shortages. Whistleblowers will receive $69M.

MedAI 8/10

Did Heart Failure Device Updates Just Shift Abbott Stock’s Investment Narrative?

Abbott Laboratories received FDA approval for upgrades to its CardioMEMS HF System and launched SimpleScreen CRC, a blood-based colorectal cancer screening test. These updates extend Abbott's reach in heart failure monitoring and early cancer detection. Analysts expect 8.8% yearly revenue growth and profit margins rising to 16.0% by 2029, with a consensus earnings forecast of $9.6b by 2029.